BCC Research Strattera ® Forecast

Report Highlights

BCC Research is pleased to announce the BCC Research Strattera ® Forecast , a strategic investment product designed to provide market data for the pharmaceutical drug Strattera ®, a treatment for Attention Deficit Hyperactivity Disorder (ADHD) distributed by Eli Lilly and Company. Strattera ® will lose its branded patent protection in late 2016 going into 2017, opening the market to distribution of generic treatments by competing companies.

With BCC Research's Strattera ® Forecast, you will have quantitative data about forecasted revenue for the pharmaceutical drug Strattera ®  that will guide you in your strategic decision-making regarding future participation in this product sector.

The BCC Research Strattera ® Forecast is a quantitative forecast model in an easily accessible Microsoft® Excel® spreadsheet,  featuring:

• Market demand forecasts for Strattera ® annually for the years 2016 to 2030 by volume (number of patients) and value (in U.S. dollars)
• Segmentation of volume and value for these regions:
• United States
• Japan
• France
• Germany
• Italy
• Spain
• United Kingdom
• Interactive data for:
• Patient volumes, with forecasts by age range and prevalence, as well as population estimates
• Product pricing forecasts

Use the BCC Research Strattera ® Forecast to:

• Examine forecasted market demand for Strattera ®
• Validate other Strattera ® market-demand data to which you have access
• Make strategic decisions about entering Strattera ®-related or Attention Deficit Hyperactivity Disorder (ADHD) treatment-related markets

Strattera ® is a registered trademark of Eli Lilly and Company. Microsoft and Excel are registered trademarks of Microsoft Corporation.

Figure 1- Summary graphs-Value in USD and Patient Volumes, by Region, 2010-2030

Table 1-Total market graphs-Revenue by Region and Patient Volumes, 2016 to 2030

Table 2-US Patient Volumes, 2010 to 2030

Table 3-Japan Patient Volumes, 2010 to 2030

Table 4-France Patient Volumes, 2010 to 2030

Table 5-German Patient Volumes, 2010 to 2030

Table 6-Italy Patient Volumes, 2010 to 2030

Table 7-Spain Patient Volumes, 2010 to 2030

Table 8-UK Patient Volumes, 2010 to 2030

Table 9-US Population Estimates, Sex and Age, 2015 to 2060

Table 10-Europe Population Estimates, 2010 to 2030

Table 11-Japan Population Estimates, 2010 to 2030

Table 12-US Pricing and FX Rates, Strattera Annual Costs, 2010 to 2030

Table 13-Japan Pricing and FX Rates, Strattera Annual Costs, 2010 to 2030

Table 14-France Pricing and FX Rates, Strattera Annual Costs, 2010 to 2030

Table 15-German Pricing and FX Rates, Strattera Annual Costs, 2010 to 2030

Table 16-Spain Pricing and FX Rates, Strattera Annual Costs, 2010 to 2030

Table 17-UK Pricing and FX Rates, Strattera Annual Costs, 2010 to 2030

Analyst Credentials

Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy, where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early- and mid-stage drug development. Jackson Highsmith is a pseudonym of the author.